Expansion of the Research Centre for Cytostatic Drugs (Q12109)

From EU Knowledge Graph
Revision as of 17:03, 28 October 2020 by DG Regio (talk | contribs) (‎Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement)
Jump to navigation Jump to search
Project Q12109 in Czech Republic
Language Label Description Also known as
English
Expansion of the Research Centre for Cytostatic Drugs
Project Q12109 in Czech Republic

    Statements

    country
    Czechia
    0 references
    EU contribution
    5,007,500.0 Czech koruna
    0 references
    200,300.0 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    10 January 2020
    0 references
    budget
    10,015,000.0 Czech koruna
    0 references
    400,600.0 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    10 January 2020
    0 references
    co-financing rate
    50 percent
    0 references
    expected end time
    30 June 2020
    0 references
    beneficiary name (string)
    VUAB Pharma a.s.
    0 references
    beneficiary
    VUAB Pharma
    0 references
    coordinate location

    50°9'46.91"N, 14°23'2.26"E
    0 references
    postal code
    25263
    0 references
    summary
    Předkládaný projekt je zaměřen na rozšíření výzkumně-vývojového centra pro urychlení a zkvalitnění vývoje konečné lékové formy léčiv nádorových onemocnění, a to jak originálních, tak generických léčiv, které bylo vybudováno v předchozích letech. a. (Czech)
    0 references
    The submitted project is aimed at expanding the research-development centre for speeding up and improving the development of the final drug form of cancer drugs, both original and generic drugs that were built in previous years. a. (English)
    point in time
    22 October 2020
    0 references

    Identifiers

    Czech Kohesio ID
    CZ.01.1.02/0.0/0.0/17_165/0015953
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q12109&oldid=6763999"